Risk of postop urinary retention may vary depending on when devices are removed.
Uropathogens may not be the only bacteria shared between the vagina and bladder.
Results of a study by Canadian researchers suggest that exposure to low and medium doses of cranberry juice may have potential to reduce physician visits and costs for women who have a history of recurrent urinary tract infection (UTI).
Results of a Phase 3 randomized clinical trial (RCT) suggest that a combination carbapenem/beta-lactamase inhibitor may have potential in treatment of severe drug-resistant gram-negative urinary tract infections (UTI).
Results of a multinational trial show that a 5-day course of nitrofurantoin may produce better outcomes in women with uncomplicated lower urinary tract infection (UTI) than a single dose of fosfomycin.
A study from Belgium has found that women with typical symptoms of urinary tract infection (UTI) may still be infected with the uropathogen Escherichia coli despite a negative culture result.
In a Swiss comparative trial, diclofenac was found to be inferior to norfloxacin for treatment of urinary tract infection (UTI).
Findings from a recent study indicate that trimethoprim 200 mg BID for 3 or 7 days is the most effective antibiotic for uncomplicated urinary tract infection (UTI) when levels of local resistance to the drug are < 30%. However, when it is ≥ 35%, a single dose of fosfomycin 3g or nitrofurantoin 100 mg BID for 7 days is more cost-effective.
This article summarizes guidelines for diagnosis and treatment, highlighting special considerations for management of OAB across a woman’s life span.
Ob/gyns have witnessed how development of antibiotic resistance has affected disease management in our specialty. Increased resistance of Neisseria. Gonorrhea (N. gonorrhea) to penicillins and quinolones, emergence of methicillin-resistant staphylococcus aureus (MRSA) and resistance of Group B Streptococcus to erythromycin and clindamycin have led us to modify our antibiotic treatment regimens.